시간 외 거래: 25.34

4D몰큘러 테라퓨틱스 (FDMT)

4D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스

4D몰큘러 테라퓨틱스 (FDMT)

4D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스

4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.6% - Defense World

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 3.6% - MarketBeat

Chief Legal Officer Bizily Scott sold 1750 shares of 4D Molecular Therapeutics Inc [FDMT] – Knox Daily - Knox Daily

4D Molecular Therapeutics Inc (FDMT) can make a big difference with a little luck – Sete News - SETE News

4D Molecular Therapeutics Inc (FDMT)'s Day in Review: Closing at 25.64, Up by 0.23 – DWinneX - The Dwinnex

New York State Common Retirement Fund Increases Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

4D Molecular Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.71) Per Share (NASDAQ:FDMT) - Defense World

4D Molecular Therapeutics (NASDAQ:FDMT) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat

HC Wainwright Analysts Boost Earnings Estimates for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

HC Wainwright Reiterates Buy Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

4D Molecular Therapeutics Inc [FDMT] Stock sold by Insider Bizily Scott for $45045.0 – Knox Daily - Knox Daily

4D Molecular Therapeutics Inc (FDMT) presents a great opportunity, but the stock is slightly undervalued – US Post News - US Post News

4D Molecular Therapeutics' (FDMT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

4D Molecular Therapeutics (FDMT) Stock Forecast and Price Target 2024 - MarketBeat

We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow - Yahoo Finance

(FDMT) Trading Signals - Stock Traders Daily

FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024 - InvestorPlace

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights - 09.05.2024 - wallstreet:online

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights - 09.05.2024 - wallstreet:online

Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength? - Yahoo Singapore News

4DMT to Participate in Upcoming Investor Conference - GlobeNewswire

4DMT to Participate in Upcoming Investor Conference - Yahoo Finance

4DMT to Participate in Upcoming Investor Conference - Yahoo Finance UK

4D Molecular Therapeutics Brings A New Dimension To Wet AMD - Scrip

Comparing Sana Biotechnology (NASDAQ:SANA) and 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance

4DMT Announces Presentations at ARVO 2024 Annual Meeting - Yahoo Canada Finance

4D Molecular Therapeutics: Pioneering Gene Therapy With Directed Evolution (NASDAQ:FDMT) - Seeking Alpha

To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation

4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform - Seeking Alpha

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares - Yahoo Finance

Vectorized biologics: are patients and payers ready to swap biologics for gene therapies? - BioCentury

Phase 3 trial for CF gene therapy 4D-710 planned for late 2025 - Cystic Fibrosis News Today

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis - GlobeNewswire

4D Molecular Therapeutics officer sells over $54k in company stock By Investing.com - Investing.com

When the Price of (FDMT) Talks, People Listen - Stock Traders Daily

4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest ... - Yahoo Finance

4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations - Yahoo Finance

4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

4DMT Reports Full Year 2023 Financial Results and Operational Highlights - Yahoo Finance

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?

Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons - BioCentury

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at ... - GlobeNewswire

4D Molecular Therapeutics Secures Major Financial Deal - TipRanks.com - TipRanks

Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts (NASDAQ:FDMT) - Seeking Alpha

FDMT과 유사한 종목